shutterstock_1492661771_ricochet64
ricochet64 / Shutterstock.com
17 September 2020Big PharmaSarah Morgan

EPO revokes Copaxone patent, clears path for Mylan

The European Patent Office (EPO) has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone (glatiramer acetate injection), in a win for Mylan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
30 September 2020   Massachusetts-based Collegium Pharmaceutical has reached a settlement agreement with Teva, resolving its patent litigation over pain medication.
Americas
16 August 2021   Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More on this story

Americas
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
30 September 2020   Massachusetts-based Collegium Pharmaceutical has reached a settlement agreement with Teva, resolving its patent litigation over pain medication.
Americas
16 August 2021   Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More on this story

Americas
23 June 2020   Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.
Americas
30 September 2020   Massachusetts-based Collegium Pharmaceutical has reached a settlement agreement with Teva, resolving its patent litigation over pain medication.
Americas
16 August 2021   Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.